CoChat

Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy

Open access

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Abstract

Although recognised as a cause of chronic diarrhoea for over forty years, diagnostic tests and treatments for bile acid malabsorption (BAM) remain controversial. Recent National Institute for Health and Care Excellence (NICE) guidelines highlighted the lack of evidence in the field, and called for further research. This retrospective study explores the BAM subtype and severity, the use and response to bile acid sequestrants (BAS) and the prevalence of abnormal colonic histology. 264 selenium-75-labelled homocholic acid conjugated taurine (SeHCAT)-tested patient records were reviewed and the severity and subtype of BAM, presence of colonic histopathology and response to BAS were recorded. 53% of patients tested had BAM, with type-2 BAM in 45% of patients with presumed irritable bowel syndrome. Colonic histological abnormalities were similar overall between patients with (29%) or without (23%) BAM (p = 0.46) and between BAM subtypes, with no significant presence of inflammatory changes. 63% of patients with BAM had a successful BAS response which showed a trend to decreased response with reduced severity. Colestyramine was unsuccessful in 44% (38/87) and 45% of these (17/38) were related to medication intolerance, despite a positive SeHCAT. 47% (7/15) of colestyramine failures had a successful colesevelam response. No patient reported colesevelam intolerance. Quantifying severity of BAM appears to be useful in predicting BAS response. Colesevelam was better tolerated than colestyramine and showed some efficacy in colestyramine failures. Colestyramine failure should not be used to exclude BAM. Colonic histology is of no relevance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7861/clinmedicine.15-3-252

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Proportion of patients with successful and unsuccessful responses to BAS for each (A) subtype and (B) severity of BAM. BAM = bile acid malabsorption; BAS = bile acid sequestrants.
Fig 1 Proportion of patients with successful and unsuccessful responses to BAS for each (A) subtype and (B) severity of BAM. BAM = bile acid malabsorption; BAS = bile acid sequestrants.CC-BY-NC-ND · From the PDF
Fig 3 Presence of colonic histological abnormalities among patients with BAM compared with those without BAM. BAM = bile acid malabsorption.
Fig 3 Presence of colonic histological abnormalities among patients with BAM compared with those without BAM. BAM = bile acid malabsorption.CC-BY-NC-ND · From the PDF
Image 3
CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. Aldridge, 2001, Colesevelam hydrochloride: a novel bile acid-binding resin, Ann Pharmacother, 35, 898, 10.1345/aph.10263 · doi:10.1345/aph.10263 · Paper page

Cited by

See all 74

Metadata

Authors
Orekoya, O., McLaughlin, J., Leitao, E., Johns, W., Lal, S., & Paine, P.
Affiliations
  • Bolton NHS Foundation Trust (GB)
  • Salford Royal NHS Foundation Trust (GB)
Venue
Clinical Medicine
Publisher
Elsevier BV
Published
2015-06
Volume
15
Issue
3
Pages
252-257
ISSN
1470-2118 (ISSN-L)
OpenAlex
W2616787139
Cited by
74
References
37
Citations by year
2026: 4 · 2025: 6 · 2024: 7 · 2023: 4 · 2022: 9 · 2021: 7 · 2020: 6 · 2019: 9 · 2018: 10 · 2017: 2 · 2016: 6 · 2015: 4
FWCI
7.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Medicine (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Gastroenterology › Digestive system and related health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
bile acid malabsorption, bile acid sequestrants, SeHCAT test, irritable bowel syndrome, chronic diarrhea, cholestyramine, colesevelam, treatment response prediction, colonic histology, drug intolerance
MeSH terms
Colesevelam Hydrochloride, Adolescent, Adult, Aged, Aged, 80 and over, Allylamine, Anticholesteremic Agents, Bile Acids and Salts, Cholestyramine Resin, Colon, Diarrhea, Female, Humans, Male, Middle Aged, Retrospective Studies, Taurocholic Acid, Steatorrhea, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy. https://app.cochat.ai/papers/10.7861/clinmedicine.15-3-252
The paper
Orekoya, O., McLaughlin, J., Leitao, E., Johns, W., Lal, S., & Paine, P. (2015). Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy. Clinical Medicine. https://doi.org/10.7861/clinmedicine.15-3-252

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.